Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Actemra: <strong>Roche</strong>’s ongoing phase III program<br />
Additional international trials<br />
TRIAL / Treatment<br />
Arms<br />
Topline Data<br />
Timing<br />
Sample<br />
Size<br />
Patient population<br />
Endpoints<br />
TOWARD<br />
Actemra 8 mg + DMARDs<br />
DMARDs<br />
Top line<br />
announced June<br />
6, 2007<br />
1’200<br />
DMARD inadequate<br />
responders<br />
ACR 20 response at Wk 24<br />
RADIATE<br />
Actemra 4 mg + MTX<br />
Actemra 8 mg + MTX<br />
2007<br />
570<br />
Anti-TNFα inadequate<br />
responders<br />
ACR 20 response at Wk24<br />
MTX<br />
AMBITION<br />
Actemra 8 mg monotherapy<br />
2007<br />
550<br />
MTX naive<br />
ACR 20 response at Wk 24<br />
MTX<br />
LITHE<br />
Actemra 4 mg + MTX<br />
Actemra 8 mg + MTX<br />
2008<br />
1’170<br />
MTX inadequate<br />
responders<br />
ACR 20 at Wk 24<br />
Sharp Score at Wk 52<br />
Sharp Score at Wk 104<br />
MTX<br />
Physical function at Wk 104<br />
Filing on track for 2007<br />
63